p53 staining as a prognostic indicator in endometrial carcinoma

European Journal of Gynaecological Oncology

Volumn 20, Issue 2, 1999, Pages 156-159

  Ozsaran A A ^a,b   Turker S ^a   Dikmen, Y ^a   Erhan, Y ^a   Itil, I ^a   Terek, C ^a   Ozdemir N ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b NONE   (Turkey)

Author keywords

Endometrial cancer; p53

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; IMMUNOPEROXIDASE STAINING; MICROSCOPY; PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, ADENOSQUAMOUS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0344267691     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Marshall C. J.: "Tumor suppressor genes". Cell, 1991, 64, 313.
2. Banks L., Matlashewski G., Crawford L.: "Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression". Eur. J. Biochem., 1986, 159, 529.
3. Gannon J. V., Greaves R., Iggo R., Lane D. P.: "Activating mutations of p53 produce a common conformational effect: a monoclonal antibody specific for the mutant form". EMBO J., 1990, 9, 1595.
4. Finlay C. A., Hinds P. W., Tan T. H., Eliyahu D., Oren G., Levine A. J.: "Activating mutations for transformation by p53 produce a gene product that forms an hsc70-patient p53 complex with an altered half-life". Mol. Cell. Biol., 1988, 8, 531.
5. Baker S. J., Preisinger A. C., Jessup J. M.: "p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis". Cancer Res., 1990, 50, 7717.
6. Levine A. J., Momand J., Finlay L. A.: "The p53 tumor suppressor gene". Nature, 1991, 351, 453.
7. Kerns B. J., Jordan P. A., Moore B. M.: "p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry". J. Histochem. Cytochem., 1992, 40, 1047.
8. Nigro J. M., Baker S. J., Preisinger A. C.: "Mutations in the p53 gene occur in diverse human tumor types". Nature, 1989, 342, 705.
9. Creasman W. T., Rutledge F.: "The prognostic value of peritoneal cytology in gynecologic malignant disease". Am. J. Obstet. Gynecol., 1971, 110, 773.
10. Hanson M. B., Van Nagell J. R., Powell D. E., Donaldson E. S., Gallion H., Merhige M.: "The prognostic significance of lymph-vascular space invasion in stage I endometrial cancer". Cancer, 1985, 55, 1753.
11. Geisinger K. R., Homesley H. D., Morgan T. M., Kute T. E., Marshall R. B.: "Endometrial carcinoma: a multiparameter clinicopathologic analysis including the DNA profile and the sex steroid status". Cancer, 1986, 58, 1518.
12. Britton L. C., Wilson T. D., Gaffey T. A., Cha S. S., Wreand H. S., Podratz K. C.: "DNA ploidy in endometrial carcinoma: major objective prognostic factor". Mayo. Clin. Proc., 1990, 65, 643.
13. Kohler M. F., Berchuck A., Davidoff A. M.: "Overexpression and mutation of p53 in endometrial carcinoma". Cancer Rex., 1992, 52, 1622.
14. Geisler J. P., Wiemann M. C., Zhou Z., Miller G. A., Geisler H. E.: "p53 as a prognostic indicator in endometrial cancer". Gynecol. Oncol., 1996, 61, 245.
15. Reinartz J. J., George E., Lindgren B. R., Niehans G. A.: "Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erb-2 in endometrial carcinoma and correlation with survival and known predictors of survival". Hum. Pathol., 1994, 25, 1075.
16. Bur M. E., Perlman C., Edelman L., Fey E., Rose P. G.: "p53 expression in neoplasms of the uterine corpus". Am. J. Clin. Pathol., 1992, 98, 81.